Related Experiment Video

Updated: Dec 29, 2025

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.5K

HDL cholesterol efflux capacity is related to disease activity in psoriatic arthritis patients

Iván Ferraz-Amaro1, María Vanesa Hernández-Hernández1, Estefanía Armas-González1

  • 1Servicio de Reumatología, Hospital Universitario de Canarias, La Laguna, Spain.

Clinical Rheumatology
|January 30, 2020
PubMed

Insights

Cholesterol efflux capacity (CEC), crucial for cardiovascular health, is not impaired in psoriatic arthritis (PsA) patients. However, higher disease activity in PsA is independently linked to reduced CEC, increasing cardiovascular risk.

Area of Science:

  • Cardiovascular Science
  • Rheumatology
  • Lipid Metabolism

Background:

  • Cholesterol efflux capacity (CEC) is a key function of high-density lipoprotein (HDL) cholesterol, vital for removing cholesterol from macrophages.
  • CEC is associated with cardiovascular event risk and can be compromised during inflammatory conditions.

Purpose of the Study:

  • To investigate whether CEC is impaired in patients with psoriatic arthritis (PsA).
  • To determine if disease activity or other PsA-related factors explain any potential impairment in CEC.

Main Methods:

  • A case-control study involving 52 PsA patients and 53 controls.
  • In vitro assessment of CEC and measurement of serum lipoprotein concentrations.
  • Disease activity in PsA patients was quantified using the Disease Activity Index for Psoriatic Arthritis (DAPSA).

Main Results:

  • PsA patients exhibited lower levels of total cholesterol, apolipoprotein A1, and LDL cholesterol compared to controls.
  • No significant difference in CEC was observed between PsA patients and controls after adjusting for cardiovascular risk factors.
  • Multivariate regression analysis revealed an independent inverse association between DAPSA score and CEC (beta coefficient -0.75, p=0.023).

Conclusions:

  • CEC is not globally impaired in PsA patients but is inversely associated with disease activity.
  • Elevated disease activity in PsA is an independent predictor of reduced CEC, highlighting its role in accelerated atherosclerosis.
  • These findings underscore the importance of managing disease activity to mitigate cardiovascular risk in PsA.
Abstract

Keywords:
Cholesterol efflux capacityDisease activityDyslipidemiaPsoriatic arthritis

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.6K
High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay08:18

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

Published on: January 7, 2019

9.5K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
279
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.2K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Inflammation01:38

Inflammation

Overview
61.2K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
692
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
388